Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. We studied the role of combination of TACE and sorafenib in BCLC stages B/C. We undertook an observational study on a cohort of cirrhotics with HCC from August 2010 throu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hepatology 2017-03, Vol.16 (2), p.247-254
Hauptverfasser:	Varghese, Joy, Kedarisetty, Chandan, Venkataraman, Jayanthi, Srinivasan, Vijaya, Deepashree, Thiruchunapalli, Uthappa, Mangerira, Ilankumaran, Kaliamurthy, Govil, Sanjay, Reddy, Mettu, Rela, Mohamed
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - mortality Female Gastroenterology & Hepatology Humans India Kaplan-Meier Estimate Liver Cirrhosis - complications Liver Neoplasms - etiology Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - therapy Male Middle Aged Neoplasm Staging Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Time Factors Treatment Outcome Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!